Since TIGIT and PD-1 are co-expressed, and dual blockade in the mouse model limits in vivo LCMV replication [18] and elicits anti-tumor CD8+ T cell responses [19], we evaluated the effects of TIGIT and PD-L1 blockade on HIV-Gag-specific CD8+ T cells using cells from chronically HIV-infected individuals at various stages of infection (Table 2). The gene discussed is CD8A; the disease is neoplasm.